A number of firms have modified their ratings and price targets on shares of Sarepta Therapeutics (NASDAQ: SRPT) recently:

  • 7/12/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $102.00 price target on the stock.
  • 7/3/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 6/30/2017 – Sarepta Therapeutics had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
  • 6/30/2017 – Sarepta Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/30/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $64.00 price target on the stock.
  • 6/23/2017 – Sarepta Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/22/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $60.00 price target on the stock.
  • 6/8/2017 – Sarepta Therapeutics was given a new $76.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 6/2/2017 – Sarepta Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 5/23/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Nomura. They now have a $84.00 price target on the stock.
  • 5/22/2017 – Sarepta Therapeutics was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $36.86 price target on the stock.
  • 5/18/2017 – Sarepta Therapeutics was given a new $43.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.

Sarepta Therapeutics, Inc. (SRPT) opened at 35.25 on Monday. The stock has a 50 day moving average price of $32.84 and a 200-day moving average price of $31.53. Sarepta Therapeutics, Inc. has a 12 month low of $19.71 and a 12 month high of $63.73. The stock’s market cap is $1.94 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, April 27th. The biotechnology company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.12. The firm had revenue of $16.34 million during the quarter, compared to the consensus estimate of $13.80 million. The business’s revenue for the quarter was up 163300.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.15) earnings per share. On average, analysts expect that Sarepta Therapeutics, Inc. will post ($0.65) EPS for the current year.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.